Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.
70 - 78
Multiple Sclerosis and Related Disorders
MetadataShow full item record
Trials of anti-inflammatory therapies in non-relapsing progressive multiple sclerosis (MS) have been stubbornly negative except recently for an anti-CD20 therapy in primary progressive MS and a S1P modulator siponimod in secondary progressive MS. We argue that this might be because trials have been too short and have focused on assessing neuronal pathways, with insufficient reserve capacity, as the core component of the primary outcome. Delayed neuroaxonal degeneration primed by prior inflammation is not expected to respond to disease-modifying therapies targeting MS-specific mechanisms. However, anti-inflammatory therapies may modify these damaged pathways, but with a therapeutic lag that may take years to manifest. Based on these observations we propose that clinically apparent neurodegenerative components of progressive MS may occur in a length-dependent manner and asynchronously. If this hypothesis is confirmed it may have major implications for the future design of progressive MS trials.
AuthorsGiovannoni, G; Cutter, G; Pia-Sormani, M; Belachew, S; Hyde, R; Koendgen, H; Knappertz, V; Tomic, D; Leppert, D; Herndon, R; Wheeler-Kingshott, CAM; Ciccarelli, O; Selwood, D; di Cantogno, EV; Ben-Amor, A-F; Matthews, P; Carassiti, D; Baker, D; Schmierer, K
- College Publications 
Showing items related by title, author, creator and subject.
Maggiore, Cosimo (Queen Mary University of London, 2013)One of the pathological features of multiple sclerosis (MS) is the presence of a long lived chronic inflammation in the central nervous system (CNS) with presence of oligoclonal IgG and IgM bands (OCBs) in the cerebrospinal ...
Development of a novel model of optic neuritis to assess neuroprotective and repair strategies in multiple sclerosis Lidster, Katie (2012)Multiple sclerosis (MS) is a putative autoimmune disease of the central nervous system (CNS), which often affects the optic nerve pathway. Optic neuritis (ON) is a clinical feature of MS that can cause loss of vision due ...
Characterisation of fatty acid amide hydrolase as a potential therapeutic target in Multiple Sclerosis. Graves, Ryan Stanley (Queen Mary University of London, 2013)Multiple sclerosis (MS) is a demyelinating neurodegenerative disease that typically has a relapsing-remitting pattern of progression superimposed on a gradual worsening of disease symptoms. Experimental autoimmune ...